| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Won Hyeok Choe | |
| Soon Young Ko | |||
| P2860 | cites work | Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment | Q26751452 |
| KASL clinical practice guidelines: management of hepatitis C | Q26752471 | ||
| Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
| Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil | Q27478301 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Hepatitis C Therapy in Renal Patients: Who, How, When? | Q28077130 | ||
| Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients | Q28079336 | ||
| Hepatitis C | Q28084654 | ||
| Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. | Q30227099 | ||
| Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 | ||
| Management of hepatitis C in patients with chronic kidney disease. | Q34932338 | ||
| Hepatitis C virus infection: when silence is deception. | Q35196430 | ||
| Current status of hepatitis C virus infection in Korea | Q36258735 | ||
| Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency | Q36518540 | ||
| Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. | Q36562355 | ||
| The changing epidemiology and natural history of hepatitis C virus infection | Q36681591 | ||
| The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies | Q36944054 | ||
| Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. | Q37362857 | ||
| The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals | Q37903174 | ||
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. | Q38971057 | ||
| Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease | Q39920614 | ||
| Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. | Q40774514 | ||
| Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. | Q40832783 | ||
| Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study | Q40957442 | ||
| Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. | Q41918943 | ||
| APASL consensus statements and recommendation on treatment of hepatitis C. | Q42400012 | ||
| Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit | Q42980352 | ||
| Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. | Q42989745 | ||
| Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin | Q42990347 | ||
| Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis | Q43047571 | ||
| Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand | Q44177155 | ||
| Antibody to hepatitis C virus increases with time on hemodialysis | Q44517525 | ||
| Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. | Q44579440 | ||
| Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members | Q45777988 | ||
| KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. | Q55049598 | ||
| Recommendations for preventing transmission of infections among chronic hemodialysis patients | Q73875597 | ||
| Acute hepatitis C among renal failure patients on chronic haemodialysis | Q77299024 | ||
| Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease | Q85415636 | ||
| EASL Recommendations on Treatment of Hepatitis C 2016 | Q88412279 | ||
| Finally, safe and effective treatment options for hepatitis C in hemodialysis patients | Q89173198 | ||
| A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies | Q93908163 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 4 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| RNA virus infectious disease | Q18967413 | ||
| antiviral agent | Q40207875 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 351-357 | |
| P577 | publication date | 2018-03-16 | |
| 2018-12-01 | |||
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals | |
| P478 | volume | 24 |
Search more.